1. トップページ
  2. 研究業績 > 原著論文(英文)

原著論文(英文)

原著論文(英文):当科医局員first authorのみ

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |  2009 | 2008 |

2019

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.
Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H. Clin Mol Hepatol. 25(1):65-73, 2019

Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Mashitani T, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yamao J, Yoshiji H. Hepatol Res. 49(3):284-295, 2019

Calcified mucinous adenocarcinoma of stomach metastatic to the iris: an autopsy case report
Kaneko M, Namisaki T, Takaya H, Mori H, Kitade M, Okura Y, Seki K, Sato S, Nakanishi K,Kitagawa K, Ozutsumi T, Shimozato N, Kaji K, Otani T, Nakai T ,Obayashi C, Mitoro A, Yamao J, Yoshiji H" Journal of Medical Case Reports 13(1):64, 2019

Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury model.
Kitade M, Kaji K, Nishimura N, Seki K, Nakanishi K, Tsuji Y, Sato S, Saikawa S, Takaya H, Kawaratani H, Namisaki T, Moriya K, Mitoro A, Yoshiji H. Hepatol Res. Epub ahead of print

Identification of clinical risk factors for histological progression of primary biliary cholangitis
Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Tak Hepatol Res. Epub ahead of print

Diagnostic Efficacy of Liquid-Based Cytology in Endoscopic Ultrasound-Guided Fine Needle Aspiration for Pancreatic Mass Lesions During the Learning Curve: A Retrospective Study.
Mitoro A, Nishikawa T, Yoshida M, Sawai M, Okura Y, Kitagawa K, Seki K, Furukawa M, Ozutsumi T, Takeuchi M, Morita K, Ohbayashi C, Yamao J, Yoshiji H. Pancreas. 2019 May/Jun 48(5):686-689, 2019

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. World J Gastrointest Oncol. 11(5):424-435, 2019

Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
Nakanishi K, Kaji K, Kitade M, Kubo T, Furukawa M, Saikawa S, Shimozato N, Sato S, Seki K, Kawaratani H, Moriya K, Namisaki T, Yoshiji H. Int J Mol Sci. 3;20(11). pii: E2724, 2019

The combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
Shimozato N, Namisaki T, Kaji K, Kitade M, Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, Sawada Y, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Asada K, Kitagawa K, Tsuji Y, Kaya D, Ozutsumi T, Akahane T, Mitoro A, Yoshiji H. Hepatol Res. Epub ahead of print

2018

[Short-term sustained virological response in a patient with liver cirrhosis, hepatitis C, and declining hepatic spare ability during treatment with direct-acting antivirals].
Mori H, Takaya H, Namisaki T, Noguchi R, Hanatani J, Kaneko M, Seki K, Okura Y, Kitade M, Mitoro A, Yamao J, Yoshiji H. Nihon Shokakibyo Gakkai Zasshi. 2018;115(5):476-484.

Cross-over study in hyperammonemia patients for efficacy, safety, and acceptability of a new lactulose preparation (SK-1202) compared to approved drug.
Yoshiji H, Karino Y, Suzuki Y, Suzuki F, Uejima M, Aikata H, Chayama K, Iwai H, Suzuki E, Kumada H. Hepatol Res. 2018 Jul 13.

Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Moriya K, Namisaki T, Sato S, Douhara A, Furukawa M, Kawaratani H, Kaji K, Kitade M, Shimozato N, Sawada Y, Seki K, Saikawa S, Takaya H, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H. J Gastrointest Oncol. 2018 Aug;9(4):741-749.

Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection.
Takeda K, Noguchi R, Namisaki T, Moriya K, Akahane T, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Fujinaga Y, Tsuji Y, Kubo T, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Mitoro A, Mashitani T, Okura Y, Yamao J, Yoshiji H. Exp Ther Med. 2018 Sep;16(3):2743-2750.

Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.
Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H. Hepatol Res. 2018 Sep 9.

A Histologically Proven Case of Autoimmune Hepatitis with Eosinophilic Fasciitis.
Asada S, Douhara A, Murata K, Yanase K, Tsutsumi M, Yoshiji H. Intern Med. 2018 Oct 17.

Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Mashitani T, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yamao J, Yoshiji H. Hepatol Res. 2018 Oct 26.

von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.
Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H. United European Gastroenterol J. 2018 Nov;6(9):1401-1409.

Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats.
Nishimura N, Kaji K, Kitade M, Aihara Y, Sato S, Seki K, Sawada Y, Takaya H, Okura Y, Kawaratani H, Moriya K, Namisaki T, Mitoro A, Yoshiji H. BMC Cancer. 2018 Nov 26;18(1):1164.

Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report.
Kaneko M, Mitoro A, Yoshida M, Sawai M, Okura Y, Furukawa M, Namisaki T, Moriya K, Akahane T, Kawaratani H, Kitade M, Kaji K, Takaya H, Sawada Y, Seki K, Sato S, Fujii T, Yamao J, Obayashi C, Yoshiji H. BMC Gastroenterol. 2018;18:16.  

Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis.
Takaya H, Kawaratani H, Kubo T, Seki K, Sawada Y, Kaji K, Okura Y, Takeda K, Kitade M, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H.
Hepatol Res. 2018;48:E52-E60.

Glycogenic Hepatopathy in Type 1 Diabetes Mellitus.
Asada S, Kawaratani H, Mashitani T, Kaya D, Nishigori M, Kubo T, Sawada Y, Fujinaga Y, Kaji K, Kitade M, Namisaki T, Moriya K, Mitoro A, Yoshiji H.
Intern Med. 2018;57:1087-1092.

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H.
Int J Cancer. 2018;142:1712-1722.

Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model.
Seki K, Kitade M, Nishimura N, Kaji K, Asada K, Namisaki T, Moriya K, Kawaratani H, Okura Y, Takaya H, Sawada Y, Sato S, Nakanishi K, Yoshiji H.
Oncotarget. 2018;9:28638-28651.

Management of refractory cirrhotic ascites: challenges and solutions.
Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H.
Hepat Med. 2018;10:55-71.

Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.
Saikawa S, Kaji K, Nishimura N, Seki K, Sato S, Nakanishi K, Kitagawa K, Kawaratani H, Kitade M, Moriya K, Namisaki T, Mitoro A, Yoshiji H.
Cancer Lett. 2018 Jul 19.

2017

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. World J Gastroenterol. 2017;23:8355-8366.

Improve gut microbiome: a new horizon of cancer therapy
Fukui H.
HepatoBiliary Surg Nutr 2017;6(6): 424-428 

Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Okura Y, Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Noguchi R, Nishimura N, Seki K, Kawaratani H, Takaya H, Sato S, Sawada Y, Shimozato N, Furukawa M, Nakanishi K, Saikawa S, Kubo T, Asada K, Yoshiji H.
Hepatol Res. 2017 Nov;47(12):1317-1328. doi: 10.1111/hepr.12860. Epub 2017 Feb 13.

Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development.
Takeda K, Noguchi R, Kitade M, Namisaki T, Moriya K, Kawaratani H, Okura Y, Kaji K, Aihara Y, Douhara A, Nishimura N, Sawada Y, Seki K, Yoshiji H.
Mol Med Rep. 2017 Nov;16(5):5752-5758. doi: 10.3892/mmr.2017.7356. Epub 2017 Aug 24.

A Patient with Hepatocellular Carcinoma with Isolated Right Atrial Metastases.
Takaya H, Kawaratani H, Seki K, Okura Y, Kitade M, Namisaki T, Sawai M, Sawada Y, Kubo T, Mitoro A, Yamao J, Yoshiji H.
Intern Med. 2017 Oct 1;56(19):2589-2594. doi: 10.2169/internalmedicine.8568-16. Epub 2017 Sep 6.

Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B.
Noguchi R, Kaji K, Namisaki T, Moriya K, Kitade M, Takeda K, Kawaratani H, Okura Y, Aihara Y, Furukawa M, Mitoro A, Yoshiji H.
World J Gastroenterol. 2017 Sep 28;23(36):6705-6714. doi: 10.3748/wjg.v23.i36.6705.

Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure.
Takaya H, Yoshiji H, Kawaratani H, Sakai K, Matsumoto M, Fujimura Y, Fukui H.
Biomed Rep. 2017 Sep;7(3):277-285. doi: 10.3892/br.2017.945. Epub 2017 Jul 19.

Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization.
Douhara A, Namisaki T, Moriya K, Kitade M, Kaji K, Kawaratani H, Takeda K, Okura Y, Takaya H, Noguchi R, Nishimura N, Seki K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Saikawa S, Nakanishi K, Furukawa M, Kubo T, Yoshiji H.
Oncol Lett. 2017 Sep;14(3):3028-3034. doi: 10.3892/ol.2017.6489. Epub 2017 Jun 28.

Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.
Kawaratani H, Fukui H, Moriya K, Noguchi R, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K, Nishimura N, Takaya H, Aihara Y, Sawada Y, Sato S, Seki K, Mitoro A, Yamao J, Yoshiji H.
Hepatol Res. 2017 Aug;47(9):854-861. doi: 10.1111/hepr.12826. Epub 2016 Nov 9.

Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review).
Kawaratani H, Moriya K, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K, Takaya H, Nishimura N, Sato S, Sawada Y, Seki K, Kubo T, Mitoro A, Yamao J, Yoshiji H.
Int J Mol Med. 2017 Aug;40(2):263-270. doi: 10.3892/ijmm.2017.3015. Epub 2017 Jun 9.

Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis.
Takaya H, Kawaratani H, Kubo T, Seki K, Sawada Y, Kaji K, Okura Y, Takeda K, Kitade M, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H.
Hepatol Res. 2017 Jun 19. doi: 10.1111/hepr.12926. [Epub ahead of print]

Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis.
Namisaki T, Moriya K, Noguchi R, Kitade M, Kawaratani H, Yamao J, Mitoro A, Yoshida M, Sawai M, Uejima M, Mashitani T, Takeda K, Okura Y, Kaji K, Takaya H, Aihara Y, Douhara A, Nishimura N, Sawada Y, Sato S, Seki K, Yoshiji H.
Hepatol Res. 2017 Mar;47(3):E178-E186. doi: 10.1111/hepr.12746. Epub 2016 Jul 21. No abstract available.

Severe Aplastic Anemia following Parvovirus B19-Associated Acute Hepatitis.
Furukawa M, Kaji K, Masuda H, Ozaki K, Asada S, Koizumi A, Kubo T, Nishimura N, Sawada Y, Takeda K, Mashitani T, Kubo M, Amano I, Ootani T, Ohbayashi C, Murata K, Ann T, Mitoro A, Yoshiji H.
Case Reports Hepatol. 2017;2017:1359486. doi: 10.1155/2017/1359486. Epub 2017 Apr 20.

Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients.
Namisaki T, Moriya K, Kitade M, Kawaratani H, Takeda K, Okura Y, Takaya H, Nishimura N, Seki K, Kaji K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Nakanishi K, Furukawa M, Saikawa S, Kubo T, Yoshiji H.
Eur J Gastroenterol Hepatol. 2017 Jan;29(1):23-30.

Aortic Valve Replacement for the Management of Heyde Syndrome: A Case Report.
Shibamoto A, Kawaratani H, Kubo T, Nishimura N, Sato S, Seki K, Sawada Y, Takaya H, Okura Y, Takeda K, Uejima M, Namisaki T, Moriya K, Mitoro A, Yamao J, Yoshiji H.
J Nippon Med Sch. 2017;84(4):193-197. doi: 10.1272/jnms.84.193.

Up to date of therapeutic approach for liver cirrhosis.
Yoshiji H.
Nihon Shokakibyo Gakkai Zasshi. 2017;114(1):8-19. doi: 10.11405/nisshoshi.114.8. Review. Japanese. No abstract available.

Gut microbiome-based therapeutics in liver cirrhosis: basic consideration for the next step.
Fukui H.
J Clin Transl Hepatol 2017;5(3): 249–260

Cytokines in hepatic injury
Fukui H.
Muriel P eds "Liver Pathophysiology, Therapies & Antioxidants" Academic press (Elsevier) London, UK, p341-354, 2017

A new link between innate immunity and hepatic metabolism: attractive unknown place to visit.
Fukui H.
HepatoBiliary Surg Nutr 2017;6(4): 264-267

2016

Cecal Tuberculosis Mimicking Submucosal Tumor.
Kawaratani H, Moriya K, Ishida K, Noguchi R, Namisaki T, Takaya H, Douhara A, Yoshiji H, Yamao J, Fujii H, Fukui H.
Intern Med. 2016;55(14):1859-63.

Treatment for cirrhotic ascites.
Kawaratani H, Fukui H, Yoshiji H.
Hepatol Res. 2016 Jul 1.

Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.
Kawaratani H, Fukui H, Moriya K, Noguchi R, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K, Nishimura N, Takaya H, Aihara Y, Sawada Y, Sato S, Seki K, Mitoro A, Yamao J, Yoshiji H.
Hepatol Res. 2016 Oct 5.

The Gut Impacts Diabetic Management Tomorrow: The Recent Messages from Intestine and Microbiota.
Fukui H
J Clin Nutr Diet. 2016, 2:4.

Endotoxin and other microbial translocation markers in the blood: A clue to understand leaky gut syndrome.
Fukui H
Cell Mol Med 2016, 2:3.

Increased intestinal permeability and decreased barrier function: Does it really influence the risk of inflammation?
Fukui H
Inflamm Intest Dis 2016;1:135-145

Evidence-based clinical practice guidelines for liver cirrhosis 2015.
Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. J Gastroenterol. 2016;51:629-650

Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis.
Namisaki T, Moriya K, Noguchi R, Kitade M, Kawaratani H, Yamao J, Mitoro A, Yoshida M, Sawai M, Uejima M, Mashitani T, Takeda K, Okura Y, Kaji K, Takaya H, Aihara Y, Douhara A, Nishimura N, Sawada Y, Sato S, Seki K, Yoshiji H.
Hepatol Res. 2016 May 18. doi: 10.1111/hepr.12746. [Epub ahead of print].

Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Nishimura N, Kitade M, Noguchi R, Namisaki T, Moriya K, Takeda K, Okura Y, Aihara Y, Douhara A, Kawaratani H, Asada K, Yoshiji H.
J Gastroenterol. 2016 Mar 29. [Epub ahead of print].

The relationship between hepatic progenitor cell-mediated liver regeneration and non-parenchymal cells.
Kitade M, Kaji K, Yoshiji H. Hepatol Res. 2016 Feb 19. doi: 10.1111/hepr.12682. [Epub ahead of print] Review.

Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Mashitani T, Noguchi R, Okura Y, Namisaki T, Mitoro A, Ishii H, Nakatani T, Kikuchi E, Moriyasu H, Matsumoto M, Sato S, An T, Morita H, Aizawa S, Tokuoka Y, Ishikawa M, Matsumura Y, Ohira H, Kogure A, Noguchi K, Yoshiji H. Biomed Rep. 2016 Feb;4(2):183-187. Epub 2016 Jan 7.

Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H.
J Gastroenterol. 2016 Feb;51(2):162-72. doi: 10.1007/s00535-015-1104-x. Epub 2015 Jul 21.

Changes of intestinal functions in liver cirrhosis.
Fukui H, Wiest R.  Inflamm Intest Dis 2016;1: 24-40

DNA methylation of angiotensin Ⅱ receptor gene in nonalcoholic steatohepatitis-related liver fibrosis
Asada K,Aihara Y, Takaya H, Noguchi R, Namisaki T, Moriya K, Uejima M, Kitade M, Mashitani T, Kakeda K, Kawaratani H, Okura Y, Kaji K, Douhara A, Sawada Y, Nishimura N, Seki K, Mitoro A, Yamao J, Yoshiji H
World J Hepatol 8(28):1194-1199 2016.10. 8

Clinical significance of the Scheuer histological staginf system for primary biliary cholangitis in Japanese patients.
Namisaki T, Moriya K, Kitade M, kawaratani H, Takeda K, Okura Y, Takaya H, Nishimura N, Seki K, Kaji K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Nakanisi K, Furukawa M, Saikawa S, Kubo T, Yoshiji H
Eur J Gastroenterol Hepatol 10.1097/MEG.0000000000000765 2016.10.17

2015

Gut microbiota and host reaction in liver diseases.
Fukui H
Microorganisms 2015;3:759-791

Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.
Fukui H
World J Hepatol 2015;7:425-42

Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?
Fukui H
World J Gastroenterol 2015;21:11584-96

Gastric adenocarcinoma of fundic gland type (chief cell predominant type) with unique endoscopic appearance curatively treated by endoscopic submucosal resection
Takeda S, Mitoro A, Namisaki T, Yoshida M, Sawai M, Yamao J, Yoshiji H, Uejima M, Moriya K, Douhara A, Seki K, Ishida K, Morita K,Noguchi R, Kitade M, Kawaratani H, Okura Y, Takaya H, Fukui H
Acta Gastroenterol Belg. 2015 Jul-Sep;78(3):340-3.

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model
Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Aihara Y, Nishimura N, Takeda K, Okura Y, Kawaratani H, Fukui H
Molecular Medicine Reports 2015. 11:1693-1700
Mol Med Rep. 2015 Mar;11(3):1693-700. doi: 10.3892/mmr.2014.2995. Epub 2014 Nov 24.

Development of Nodular Regenerative Hyperplasia(NRH) with Portal Hypertension Following the Administration of Oxaliplatin for the Recurrence of Colon Cancer
Takaya H, Kawaratani H, Nakanishi K, Takeyama S, Morioka C, Sawai M, Toyohara M, Fujimoto M, Yoshiji H,
Yamao J, Fukui H
Intern Med. 2015;54(4):383-7. doi: 10.2169/internalmedicine.54.2461.

2014

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Aihara Y, Nishimura N, Takeda K, Okura Y, Kawaratani H, Fukui H.
Mol Med Rep. 2015 Mar;11(3):1693-700. doi: 10.3892/mmr.2014.2995. Epub 2014 Nov 24.

Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma.
Namisaki T, Schaeffeler E, Fukui H, Yoshiji H, Nakajima Y, Fritz P, Schwab M, Nies AT.
Drug Metab Dispos. 2014 Dec;42(12):2033-40. doi: 10.1124/dmd.114.059832. Epub 2014 Sep 17.

Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Kawaratani H, Nishimura N, Fukui H.
J Gastroenterol. 2014 Oct;49(10):1421-9. doi: 10.1007/s00535-013-0906-y. Epub 2013 Nov 7.

Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats.
Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, Moriya K, Kawaratani H, Shirai Y, Yoshii J, Yanase K, Kitade M, Namisaki T, Fukui H.
J Gastroenterol. 2014 Mar;49(3):481-91. doi: 10.1007/s00535-013-0783-4. Epub 2013 Mar 12.

2013

The Effect of Inflammatory Cytokines in Alcoholic Liver Disease.
Kawaratani H, Tsujimoto T, Douhara A, Takaya H, Moriya K, Namisaki T, Noguchi R, Yoshiji H, Fujimoto M, Fukui H.
Mediators Inflamm. 2013;2013:495156. Epub 2013 Dec 9. Review.

Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Kawaratani H, Nishimura N, Fukui H.
J Gastroenterol. 2013 Nov 7. [Epub ahead of print]

Cholangiocarcinoma developed in a patient with IgG4-related disease.
Douhara A, Mitoro A, Otani E, Furukawa M, Kaji K, Uejima M, Sawai M, Yoshida M, Yoshiji H, Yamao J, Fukui H.
World J Gastrointest Oncol. 2013 Aug 15;5(8):181-5. doi: 10.4251/wjgo.v5.i8.181.

Liver abscesses after peritoneal venous shunt.
Kawaratani H, Tsujimoto T, Kubo T, Aihara Y, Takaya T, Uejima M, Moriya K, Noguchi R, Yoshiji H, Fukui H.
Case Rep Gastroenterol. 2013 May 28;7(2):245-50. doi: 10.1159/000351833. Print 2013 May.

Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance.
Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Yamao J, Fujimoto M, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Uejima M, Uemura M, Fukui H.
Oncol Rep. 2013 Aug;30(2):545-52. doi: 10.3892/or.2013.2497. Epub 2013 May 27.

Large cell neuroendocrine carcinoma presenting with neck swelling in the submandibular gland: a case report.
Kawaratani H, Tsujimoto T, Yoshikawa M, Kawanami F, Shirai Y, Yoshiji H, Morita K, Fukui H.
J Med Case Rep. 2013 Mar 19;7(1):81. doi: 10.1186/1752-1947-7-81.

Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats.
Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, Moriya K, Kawaratani H, Shirai Y, Yoshii J, Yanase K, Kitade M, Namisaki T, Fukui H.
J Gastroenterol. 2013 Mar 12. [Epub ahead of print]

Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
Aihara Y, Yoshiji H, Noguchi R, Kaji K, Namisaki T, Shirai Y, Douhara A, Moriya K, Kawaratani H, Fukui H.
Hepatol Res. 2013 Jan 29. doi: 10.1111/hepr.12081. [Epub ahead of print]

Difficulty in evaluating intestinal permeability in patients with liver cirrhosis: What is the precipitating factor?
Fukui H.
Hepatol Res. 2013 Feb;43(2):179-81. doi: 10.1111/j.1872-034X.2012.01104.x. No abstract available.

Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y, Yoshiji H, Noguchi R, Kaji K, Aihara Y, Douhara A, Moriya K, Namisaki T, Kawaratani H, Fukui H.
J Gastroenterol Hepatol. 2013 Apr;28(4):723-30. doi: 10.1111/jgh.12112.

2012

Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis.
Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Aihara Y, Shirai Y, Namisaki T, Kitade M, Douhara A, Moriya K, Fukui H.
Hepatol Res. 2013 Jul;43(7):765-74. doi: 10.1111/hepr.12008. Epub 2012 Nov 20.

A case of severe acalculous cholecystitis associated with sorafenib treatment for advanced hepatocellular carcinoma.
Aihara Y, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Morioka C, Kaji K, Tastumi H, Nakanishi K, Nakamura M, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Uemura M, Fukui H.
World J Gastrointest Oncol. 2012 May 15;4(5):115-8. doi: 10.4251/wjgo.v4.i5.115.

Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress.
Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Shirai Y, Douhara A, Fukui H.
Curr Med Chem. 2012;19(12):1889-98. Review.

Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis.
Tsujimoto T, Kawaratani H, Kitazawa T, Uemura M, Fukui H.
Dig Dis Sci. 2012 May;57(5):1144-51. doi: 10.1007/s10620-012-2073-z. Epub 2012 Feb 25.

ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score.
Takaya H, Uemura M, Fujimura Y, Matsumoto M, Matsuyama T, Kato S, Morioka C, Ishizashi H, Hori Y, Fujimoto M, Tsujimoto T, Kawaratani H, Toyohara M, Kurumatani N, Fukui H.
Hepatol Res. 2012 May;42(5):459-72. doi: 10.1111/j.1872-034X.2011.00950.x. Epub 2012 Jan 31.

2011

Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Douhara A, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Fukui H.
Mol Med Report. 2012 Feb;5(2):539-44. doi: 10.3892/mmr.2011.676. Epub 2011 Nov 15.

A histologically proven case of progressive liver sarcoidosis with variceal rupture.
Yoshiji H, Kitagawa K, Noguchi R, Uemura M, Ikenaka Y, Aihara Y, Nakanishi K, Shirai Y, Morioka C, Fukui H.
World J Hepatol. 2011 Oct 27;3(10):271-4.

Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.
Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H.
Int J Hepatol. 2011;2011:759047. Epub 2011 Jul 18.

Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Fukui H.
Oncol Rep. 2011 Dec;26(6):1547-53. doi: 10.3892/or.2011.1433. Epub 2011 Aug 24.

A case of lobulated and pedunculated duodenal hyperplastic polyp treated with snare polypectomy.
Kawaratani H, Tsujimoto T, Nishimura N, Taniguchi T, Shirai Y, Kin K, Nakayama M, Fujii H, Fukui H.
Case Rep Gastroenterol. 2011 May;5(2):404-10. Epub 2011 Jul 21.

Rapid detection of spontaneous bacterial peritonitis by granulocyte elastase latex immunoassay and reagent strip.
Yamazaki M, Sano R, Kuramoto C, Yoshiji H, Uemura M, Fukui H, Kamiya M, Okamoto Y.
Rinsho Byori. 2011 Jun;59(6):549-58.

Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Shirai Y, Yoshii J, Yanase K, Fukui H.
Int J Mol Med. 2011 Jul;28(1):81-8. doi: 10.3892/ijmm.2011.658. Epub 2011 Mar 23.

Salvage living donor liver transplantation after percutaneous transluminal angioplasty for recurrent Budd-Chiari syndrome: a case report.
Shirai Y, Yoshiji H, Ko S, Yamazaki M, Ikenaka Y, Noguchi R, Morioka C, Kaji K, Aihara Y, Nakanishi K, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Uemura M, Nakajima Y, Fukui H.
J Med Case Reports. 2011 Mar 29;5(1):124.

Impact of Renin-Angiotensin System in Hepatocellular Carcinoma.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Fukui H.
Curr Cancer Drug Targets. 2011 Mar 14.

Combination Treatment of Angiotensin-II Type I Receptor Blocker and New Oral Iron Chelator Attenuates Progression of Non-alcoholic Steatohepatitis in Rats.
Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, Aihara Y, Namisaki T, Yoshii J, Yanase K, Tsujimoto T, Kawaratani H, Fukui H.
Am J Physiol Gastrointest Liver Physiol. 2011 Mar 3. [Epub ahead of print]

How leaky gut and endotoxemia induce bacterial infection in cirrhosis and gastrointestinal hemorrhage?
Fukui H.
J Gastroenterol Hepatol. 2011 Mar;26(3):423-5. [Epub ahead of print]

Therapeutic effects of cytokine modulator Y-40138 in the rat alcoholic liver disease model.
Kawaratani H, Tsujimoto T, Kitazawa T, Yoshiji H, Uemura M, Fukui H.
J Gastroenterol Hepatol. 2011 Jan 20. [Epub ahead of print]

Modulated differentiation of embryonic stem cells into hepatocyte-like cells by coculture with hepatic stellate cells.
Nishiofuku M, Yoshikawa M, Ouji Y, Saito K, Moriya K, Ishizaka S, Nishimura F, Matsuda R, Yamada S, Fukui H.
J Biosci Bioeng. 2011 Jan;111(1):71-7.

2010

Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Kawaratani H, Tsujimoto T, Fukui H. Oncol Lett. 2011 Jan;2(1):69-73. Epub 2010 Oct 5.

Pseudomembranous colitis complicating ulcerative colitis.
Kawaratani H, Tsujimoto T, Toyohara M, Kin K, Taniguchi T, Shirai Y, Ikenaka Y, Nakayama M, Fujii H, Fukui H.Dig Endosc. 2010 Oct;22(4):373-5.

The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure.
Namisaki T, Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Shirai Y, Aihara Y, Yoshii J, Yanase K, Tsujimoto T, Kawaratani H, Fukui H.
J Angiogenes Res. 2010 Aug 24;2:16.

Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor miglitol.
Kojima K, Tsujimoto T, Fujii H, Morimoto T, Yoshioka S, Kato S, Yasuhara Y, Aizawa S, Sawai M, Makutani S, Yamamoto K, Mochi T, Fukui H.
Intern Med. 2010;49(15):1545-8. Epub 2010 Aug 2. Review.

Selective aldosterone blocker ameliorates the progression of nonalcoholic steatohepatitis in rats.
Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Shirai Y, Yamazaki M, Namisaki T, Kitade M, Yoshii J, Yanase K, Tsujimoto T, Fukui H.
Int J Mol Med. 2010 Sep;26(3):407-13.

Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats.
Kitazawa T, Tsujimoto T, Kawaratani H, Fukui H.
J Gastroenterol Hepatol. 2010 May;25(5):1009-12.

Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice.
Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, Yoshii J, Yanase K, Namisaki T, Yamazaki M, Tsujimoto T, Kawaratani H, Fukui H.
Hepatol Res. 2010 May;40(5):540-9. Epub 2010 Apr 14.

Pivotal role of ADAMTS13 function in liver diseases.
Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H.
Int J Hematol. 2010 Jan;91(1):20-9. Review.

2009

Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia.
Ishikawa M, Uemura M, Matsuyama T, Matsumoto M, Ishizashi H, Kato S, Morioka C, Fujimoto M, Kojima H, Yoshiji H, Tsujimoto T, Takimura C, Fujimura Y, Fukui H.
Alcohol Clin Exp Res. 2010 Feb;34 Suppl 1:S25-33. Epub 2009 Dec 16.

Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.
Yoshiji H, Noguchi R, Kaji K, Ikenaka Y, Shirai Y, Namisaki T, Kitade M, Tsujimoto T, Kawaratani H, Fukui H.
J Gastroenterol. 2009 Nov 26.

Immunotherapy for nonalcoholic steatohepatitis using the multiple cytokine production modulator Y-40138.
Tsujimoto T, Kawaratani H, Kitazawa T, Yoshiji H, Fujimoto M, Uemura M, Fukui H.
World J Gastroenterol. 2009 Nov 28;15(44):5533-40.

Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis.
Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Yamazaki M, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Sawai M, Yoshida M, Morioka C, Tsujimoto T, Kawaratani H, Fukui H.
World J Gastroenterol. 2009 Nov 7;15(41):5193-9.

Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.
Noguchi R, Yoshiji H, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Kawaratani H, Fukui H.
Oncol Rep. 2009 Aug;22(2):355-60.

Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H.
J Hepatol. 2009 Aug;51(2):315-21. Epub 2009 May 15.

Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats.
Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y, Namisaki T, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Akahane T, Kawaratani H, Uemura M, Fukui H.
J Gastroenterol. 2009;44(5):483-91. Epub 2009 Mar 25.

Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury.
Kitazawa T, Tsujimoto T, Kawaratani H, Fukui H.
J Gastroenterol Hepatol. 2009 Jun;24(6):1089-94. Epub 2009 Feb 15.

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.
Yoshiji H, Noguchi R, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Shirai Y, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Kawaratani H, Akahane T, Aihara Y, Fukui H.
BMC Res Notes. 2009 May 5;2:70.

Simultaneous endoscopic removal of 5 coins from the stomach without causing mucosal injury using specially designed devices.
Tsujimoto T, Fujii H, Kawaratani H, Sakurai S, Kojima H, Fukui H.
Indian J Gastroenterol. 2009 Jan-Feb;28(1):33-4. Epub 2009 Jun 6.

Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report.
Mashitani T, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Ishikawa M, Kawaratani H, Matsuo N, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Sawai M, Morioka C, Tsujimoto T, Kitade M, Kaji K, Aihara Y, Fukui H.
Cases J. 2009 Jan 7;2(1):18.

2008

Embryonic stem cells reduce liver fibrosis in CCl4-treated mice.
Moriya K, Yoshikawa M, Ouji Y, Saito K, Nishiofuku M, Matsuda R, Ishizaka S, Fukui H.
Int J Exp Pathol. 2008 Dec;89(6):401-9.

Impact of insulin resistance on the progression of chronic liver diseases.
Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Yoshii J, Yanase K, Namisaki T, Yamazaki M, Moriya K, Tsujimoto T, Kawaratani H, Akahane T, Uemura M, Fukui H.
Int J Mol Med. 2008 Dec;22(6):801-8.

Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet.
Kawaratani H, Tsujimoto T, Kitazawa T, Kitade M, Yoshiji H, Uemura M, Fukui H.
World J Gastroenterol. 2008 Nov 21;14(43):6655-61.

Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: a case report and review of the literature.
Tsujimoto T, Shioyama E, Moriya K, Kawaratani H, Shirai Y, Toyohara M, Mitoro A, Yamao J, Fujii H, Fukui H.
World J Gastroenterol. 2008 Oct 21;14(39):6087-92. Review.

Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model.
Tsujimoto T, Kawaratani H, Kitazawa T, Hirai T, Ohishi H, Kitade M, Yoshiji H, Uemura M, Fukui H.
World J Gastroenterol. 2008 Oct 21;14(39):6036-43.

Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis.
Morioka C, Uemura M, Matsuyama T, Matsumoto M, Kato S, Ishikawa M, Ishizashi H, Fujimoto M, Sawai M, Yoshida M, Mitoro A, Yamao J, Tsujimoto T, Yoshiji H, Urizono Y, Hata M, Nishino K, Okuchi K, Fujimura Y, Fukui H.
Scand J Gastroenterol. 2008;43(11):1387-96.

Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis.
Uemura M, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, Isonishi A, Ishikawa M, Yagita M, Morioka C, Yoshiji H, Tsujimoto T, Kurumatani N, Fukui H.
Thromb Haemost. 2008 Jun;99(6):1019-29.

Potential role of ADAMTS13 in the progression of alcoholic hepatitis.
Uemura M, Fujimura Y, Matsuyama T, Matsumoto M, Ishikawa M, Ishizashi H, Kato S, Tsujimoto T, Fujimoto M, Yoshiji H, Morioka C, Fukui H.
Curr Drug Abuse Rev. 2008 Jun;1(2):188-96. Review.

Recent developments in the treatment of alcoholic chronic pancreatitis.
Tsujimoto T, Kawaratani H, Yoshiji H, Uemura M, Fukui H.
Curr Drug Abuse Rev. 2008 Jun;1(2):197-202. Review.

Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization.
Noguchi R, Yoshiji H, Ikenaka Y, Kitade M, Kaji K, Yoshi J, Yanase K, Namisaki T, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H.
Int J Oncol. 2008 Jan;32(1):193-9.